The aim of this study was to evaluate whether PSPs have a positive impact on adherence across a range of DMTs for first-line treatment of relapsing-remitting multiple sclerosis (RRMS), independent of the treatment duration, in a real-world setting in Germany.
DIMETHYL FUMARATE COPAY ASSISTANCE TEVA PSP
PSP impact has been evaluated mostly for persistence (continuation) and for single DMTs, less for adherence (DMT dosing behavior over time) and across a spectrum of DMTs. Patients and healthcare professionals commonly consider patient support programs (PSPs) to increase adherence to disease-modifying therapies (DMTs) in multiple sclerosis (MS). In summary, physicians should actively advise patients with MS to participate in PSPs and, together with their patients, consider achievable real-world adherence under different DMTs when deciding MS treatment strategies. PSP participation and patient awareness were low, and real-world adherence levels were found to be higher with self-injectable DMTs than with oral DMTs. The majority of PSP participants also believe in this positive effect. We consider this study to have shown that PSPs have a positive impact on adherence to DMTs in MS, independent of the treatment duration on DMT. The observed rate of PSP participation (7.6%) was significantly lower than reported in earlier studies ( P < 0.0001) PSP awareness among patients analyzed was low (22.3%). Adherence across DMTs was significantly higher for PSP participants (92.9%) compared with non-participants (61.8%) ( P = 0.0197). One hundred eighty-four patients were analyzed (mean age: 44.6 years 73.4% female mean time on DMT: 7.2 years). The primary objective was to evaluate the impact of PSPs on adherence across different DMTs by comparing patients with PSP participation versus no participation adherence was defined as not missing a single dose of DMT. Patients reported their DMT adherence using patient adherence questionnaires at four visits during an observation period of 24 weeks PSP participation for this period was reported at the last visit. This was a non-interventional, prospective, cross-sectional, multi-center study with patient-reported outcomes. This study evaluated whether PSPs have a positive impact on adherence to DMTs among patients with mild-to-moderate relapsing-remitting multiple sclerosis (RRMS) in Germany, independent of the treatment duration on DMT. PSPs are managed offerings typically encompassing nurse services, phone services, online resources, or mobile offerings. DMT manufacturers offer patient support programs (PSPs) to increase adherence. Disease-modifying therapies (DMTs) in multiple sclerosis (MS) are chronic therapies, and patients are likely to face challenges in adhering to DMT dosing regimens over time.
0 kommentar(er)
